背景:在 III 期 KEYNOTE-189 研究 (NCT02578680) 中,一线帕博利珠单抗 (pembro) + 培美曲塞 (pem) 和铂类 对比 安慰剂 (pbo) + pem 和铂类,显着提高了先前未治疗的、不存在 EGFR/ALK突变的、转移性非鳞状 NSCLC…
In order to assess the safety of the combination, we evaluated time to onset and resolution of Grade 3-5 adverse events (AEs) and subsequent treatment discontinuation in patients receiving Pem+Plat+Pembro or Placebo.Methods: The all-subjects-as-treated (ASaT) population in KEYNOTE-189 was ...
NSCLC.Methods: Pts with previously untreated stage IV nonsquamous NSCLC, no EGFR or ALK alteration, and ECOG PS 0-1 were randomized 2:1 to 4 Q3W cycles of pembro 200 mg or placebo + pem 500 mg/m2 + carboplatin AUC 5 or cisplatin 75 mg/m2 followed by maintenance pembro or placebo +...
532PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?D. Rodriguez Abreu, M.C. Garassino, E. Esteban, G. Speranza, E. Felip, M. Domine, M...
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR studydoi:10.1016/S2666-1683(22)02554-XM.H. VossT. Powles
Objectives: Results from a phase 1b/2 study showed lenvatinib (LEN) + pembrolizumab (pembro) has efficacy in patients (pts) with advanced endometrial carcinoma following prior treatment. Here, we describe the phase III study results of LEN + pembro vs treatment of physician's choice (TPC) ...